Correlation of serum levels of soluble intercellular adhesion molecule-1 with disease activity in systemic lupus erythematosus

Abstract

Intercellular adhesion molecule-1 (ICAM-1) is a membrane-bound molecule primarily involved in cell-cell adhesive interactions of the immune system. It is a cytokine-induced glycoprotein involved in the recruitment of cells into tissues undergoing inflammatory responses. The levels of soluble ICAM-1 were measured in sera of patients with systemic lupus erythematosus (SLE) using sandwich enzyme-linked immunoassay. Serum levels (mean +/- SD) of soluble ICAM-1 (sICAM-1) were significantly higher in 24 patients with SLE than in 20 controls (372+/-42 ng/dL vs 231+/-29 ng/dL, P < 0.001). A statistically significant positive correlation was observed between sICAM-1 levels and SLE disease activity index (SLEDAI) score in SLE patients, and no correlation was found between sICAM-1 and CRP, SLEDAI and CRP, or SLEDAI and ESR in patient groups (P>0.05). These findings suggest that sICAM-1 measurement may serve as an additional serologic marker of disease activity in patients with SLE.

Levels of soluble intercellular adhesion molecule‐1 and total sialic acid in serum of patients with colorectal cancer

“…The cellular source of soluble ICAM-1 (sICAM-1) in samples of healthy blood donors seemed to be from mononuclear cell, because sICAM-1 was only detectable in cell culture supernatants of lymphoid cell lines and peripheral blood mononuclear cell cultures. Raised values of sICAM-1 have been reported in samples of patients with melanoma [6], systemic lupus erythematosus [10], metastatic cancer, and acute urolithiasis [6]. Our data confirm this condition in colorectal cancer patients for the first time.…”

“…Lipid-bound SA levels are correlated with the stage of the disease, degree of metastatic involvement, and recurrence of disease [11]. Serum TSA has been found to be increased in malignant melanoma [13], colorectal cancer [10], gastric cancer [16], head and neck cancer [14], laryngeal cancer [4], and breast cancer [15] and higher TSA levels were observed in cases of more developed malignancies [11]. In addition, these concentrations have been found to be higher in colorectal cancers [11].…”

“…ICAM-1, the inducible ligand for lymphocyte function associated antigen-1 (LFA-1) and Mac-1, is found on endothelial cells, leukocytes, and some epithelial tissue, and plays a major role in cell-cell interactions in inflammatory and immune response [5][6][7]. In previous reports, an elevation of serum ICAM-1 or soluble variant of ICAM-1 (sICAM-1) was seen in patients with gastric and pancreatic carcinoma [1,8,9], melanoma, metastatic cancer and urolithiasis [6], systemic lupus erythematosus [10]. In addition, the concentrations were found to be related with staging and metastasis [1].…”

The complement cascade: Yin–Yang in neuroinflammation – neuro‐protection and ‐degeneration

“…This is in line with studies that show reduced CNS pathology on ICAM‐1 inhibition in patients and mouse models (Brey et al. 1997; Sari et al. 2002).…”

Endothelial Dysfunction in Chronic Inflammatory Diseases

“…Several other groups have attempted to correlate adhesion molecule levels with markers of disease activity. The results have been widely variable, although at least two studies demonstrated a correlation between VCAM-1 levels and disease activity [62,63,64]. Given the heterogeneity between studies and the disparate patterns of results, it is difficult to conclude that patients with SLE exhibit a distinct profile of adhesion molecule expression.…”